Dr. Casirati is a hematologist with 5 years of clinical experience in the treatment of hematological malignancies and hematopoietic stem cell transplantation, with a specific interest in acute leukemias. He devoted the last three years to translational research, to unravel the mechanisms underlying acute myeloid leukemia (AML) resistance to chemotherapy and its dynamics leading to relapse.
In Dr. Bernhard Gentner’s lab at San Raffaele Telethon Institute for Gene Therapy (Milan) he studied the role of miR-126 and its correlation with AML repopulating capacity. Furthermore, by exploiting single cell RNA sequencing of primary patient samples, he contributed to the definition of a common developmental hierarchy which accounts for the intra-tumoral heterogeneity of NPM1-mutated AML cells (manuscript in preparation).
In 2020 Dr. Casirati decided to join the Genovese lab at Dana Farber Cancer Institute to carry on an innovative research project towards future clinical translation. By taking advantage of state-of-the-art gene editing protocols, he is working to improve the efficacy of novel cellular immunotherapies, such as CAR-T cells. If successful, the results of his work could be instrumental for a swift clinical translation leading to better outcomes for high-risk AML patients.